Skip to content
PEPTIDE DOSAGESAUSTRALIA
Comparisons7 min read5 August 2026

AOD-9604 vs Tirzepatide: Two Approaches to Fat Loss Research

Comparing AOD-9604 (direct fat metabolism via GH fragment) with tirzepatide (appetite and metabolic regulation via GIP/GLP-1) — two mechanistically distinct approaches to body composition research in test subjects.

Historical research article — verify before use: Some older examples, including amounts, routes, diluents and storage windows, have not been individually rechecked against current primary sources and may not apply to any human or supplier vial. Always check the exact product's formulation, primary sources and current licensed instructions before interpreting preparation or dosing information.

Table of Contents

Overview: Direct Lipolysis vs Metabolic Regulation

AOD-9604 and tirzepatide both feature in body composition research but work through entirely different mechanisms. AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that directly stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without affecting blood glucose or IGF-1 levels. Tirzepatide is a dual GIP/GLP-1 receptor agonist that reduces body weight through appetite suppression, delayed gastric emptying, and enhanced metabolic efficiency. Their different mechanisms make them suitable for different research questions in test subjects. For research purposes only.

Head-to-Head Comparison Table

Mechanism: AOD-9604 = Direct lipolysis (GH fragment) | Tirzepatide = Appetite/metabolic regulation (GIP/GLP-1) Appetite effect: AOD-9604 = None | Tirzepatide = Strong suppression Direct fat burning: AOD-9604 = Yes | Tirzepatide = Indirect Blood glucose effect: AOD-9604 = None | Tirzepatide = Improves insulin sensitivity Dose: AOD-9604 = 300-500 mcg daily | Tirzepatide = 2.5-15 mg weekly Frequency: AOD-9604 = Daily | Tirzepatide = Once weekly GI side effects: AOD-9604 = None | Tirzepatide = Common (nausea during titration) Muscle preservation: AOD-9604 = Neutral | Tirzepatide = May reduce lean mass Research stage: AOD-9604 = Phase 2 (mixed results) | Tirzepatide = Phase 3 (strong results) Cost: AOD-9604 = Lower | Tirzepatide = Higher

Which to Choose for Research

Choose AOD-9604 when: The protocol investigates direct lipolytic mechanisms without appetite or metabolic confounders, the research requires a peptide that does not affect blood glucose or insulin, or the study examines GH-fragment fat metabolism pathways in test subjects. Choose tirzepatide when: Maximum body composition change is the research objective, the protocol investigates incretin-mediated metabolic effects, or the study requires a peptide with robust Phase 3 clinical data in test subjects. AOD-9604 offers a mechanistically cleaner approach to studying direct fat metabolism, while tirzepatide produces larger overall body composition changes through multiple metabolic pathways. For research purposes only.
Related Topics
AOD-9604 vs tirzepatidefat loss peptide comparisonAOD-9604 mechanismlipolysis vs appetite suppressionbody composition peptides

Check the concentration arithmetic

Use the calculator only after verifying a vial's content and actual final liquid volume. It is not a dosing instruction.

Open Calculator →

Related Articles

Comparisons

BPC-157 vs TB-500: What the Research Actually Shows

6 min read
Comparisons

Tirzepatide vs Semaglutide: Dual vs Single Agonist Comparison

9 min read
Comparisons

Tirzepatide vs Retatrutide: Dual vs Triple Agonist Comparison

8 min read

Disclaimer: This content is for educational and research purposes only. Supplier research products are not medicines approved for human use. Always consult relevant regulations and current product information.